Teva Pharmaceutical Industries Ltd. — Director's Dealing 2024

Mar 7, 2024

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response ... 0.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person Sabag Mark	2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited TEVA	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner
(Last) (First) (Middle) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St.,	3. Date of Earliest Transaction (Month/Day/Year) 03/05/2024	Officer (give title below) Other (specify below) EVP, International Markets
(Street) Tel Aviv, L3 6944020 (City) (State) (Zip)	4. If Amendment, Date Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

l .Title of Security Instr. 3)	2. Transaction Date (Month/Day/Year) any	2A. Deemed Execution Date, if Code	3. Transaction (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	Form:	7. Nature Ownership of Indirect Beneficial
		(Month/Day/Year)	Code		Amount	(A) Or D)	Price	(Instr. 3 and 4)	Direct (D) Ownership or Indirect (Instr. 4) (1) (Instr. 4)
'Ordinary Shares (1)	03/05/2024		M		23,764	H	(2)	424.457	D
'Ordinary Shares (1)	03/05/2024		M		58,133	ત	(2)	482,590	D

Ordinary Shares (1)	03/05/2024	S		382,590	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Derivative Security (Instr. 3)	2 Conversion Date Price of Derivative Security	3. Transaction or Exercise (Month/Day/Year) any	3A. Deemed Execution Date, if Transaction of Derivative (Month/Day/Year) (Instr. 8)	4. Code	5. Number Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Security (Instr. 5)	8. Price of 9. Number of Derivative Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10 Ownership of Indirect Form of Security: Direct (D) or Indirect (Instr. 4)	11. Nature Beneficial Derivative Ownership (Instr. 4)
				Code	(A)	(D)	Date Exercisable Date	Expiration	Title	Amount or Number of Shares
Restricted Share Units	(2)	03/05/2024		M		23,764	(4)	(4)	Ordinary Shares (1)	23,764	\$ 0	23,765	D
Restricted Share Units	(2)	03/05/2024		M		58,133	(5)	(5)	Ordinary Shares (1)	58,133	\$ 0	0	D

Explanation of Responses:

• 1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
• 1. Each restricted share uniting to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compansation Committee, the easts vale of one ordinary share.
• 1. The price in Column 4 is a weighted averes old in multiple transactions at prices ranging from \$1.4 1 of \$1.66, inclusive. The reporting person undertakes to provide, upon request by the issuer, or any security holder of the issue, full information regarding the number of shares sold at each separate price.
• 1. Restricted share were granted on March 5, 2021, with 23, 2022, March 5, 2022, March 5, 2022, March 5, 2024, and 23,765 vesting on March 5, 2025,
• 1. Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024.

Signatures

/s/ Dov Bergwerk as attorney-in-fact for Mark Sabag 03/07/2024

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly.

• * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
• ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 18tf(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of in this form are not required to respond unless the form displays a currently valid OMB Number.